Trial · NCT06955923
Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty
NCT06955923, Phase 2, Completed, David Grant U.S. Air Force Medical Center; results first posted 2026-02-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty. Trials, record NCT06955923. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06955923
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trigger Point Injection in Reducing Pain Following Total Knee Arthroplasty
- NCT number
- NCT06955923
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 11 participants, actual
- Lead sponsor
- David Grant U.S. Air Force Medical Center
- Conditions
- Trigger Point Pain, Myofascial
- Interventions
- Trigger point injection (lidocaine), Sham Comparator
- First posted
- 2025-05-02
- Last updated
- 2026-02-12
- Results first posted
- 2026-02-12
- Limitations and caveats
- Convenience sampling, Hawthorne effect, Sample Size, Peri-articular musculature targeted, Generalizability
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Scores on the Visual Analog Scale | From enrollment to the end of treatment at 6 weeks | 1\. Change in Visual Analog Scale (VAS) pain scores The VAS is a numbered scale assessing pain severity using a number which describes the average level of pain since being discharged. Participants are to put a hash mark "/" on a numbered scale ranging from 0-100. Zero (0) is no pain and 100 is severe intolerable pain |
| Secondary | Opioid Use | From enrollment to the end of treatment at 6 weeks | 1\. Compare the total opioid use between study groups (experimental, sham comparator). Opioid use will be measured during their inpatient stay using the Medication Administration Record (MAR) Summary in the electronic medical record; and completing an Opioid Use questionnaire and counting the number of pills remaining during post-operative/follow-up study visits. Inpatient opioid use will be calculated by using the morphine dosage and number of doses per day. Outpatient opioid use will be obtained by reviewing responses to the Opioid Use questionnaire and counting the number of pills remaining from the prescription given at the time of discharge. Participants will be asked to bring their medication (opioids) to their post-operative/follow-up study visits. This method will allow the investigator to measure total opioid use (injectable and pill) during their inpatient and outpatient course. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pain Scores on the Visual Analog Scale | From enrollment to the end of treatment at 6 weeks | Limited timeline for follow-up restricted total number of participants for the last follow-up interval (6 week) | Pain Scores on the Visual Analog Scale | MEAN |
| SECONDARY | Opioid Use | From enrollment to the end of treatment at 6 weeks | Due to time constraints our study was only able to evaluate 3 participants in each arm of the study on the 6 week post-operative appointment. | MME | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pain Scores on the Visual Analog Scale | Experimental Group - Participants Receiving Trigger Point Injections | Change from Baseline to Post Operative Day (POD) 1 | 51 | Standard Deviation 29.51 | Pain Scores on the Visual Analog Scale |
| Pain Scores on the Visual Analog Scale | Sham Comparator - Participants Not Receiving Trigger Point Injections | Change from Baseline to Post Operative Day (POD) 1 | 55 | Standard Deviation 22.64 | Pain Scores on the Visual Analog Scale |
| Pain Scores on the Visual Analog Scale | Experimental Group - Participants Receiving Trigger Point Injections | Change from POD1 to week 2 follow-up | 40 | Standard Deviation 14.49 | Pain Scores on the Visual Analog Scale |
| Pain Scores on the Visual Analog Scale | Sham Comparator - Participants Not Receiving Trigger Point Injections | Change from POD1 to week 2 follow-up | 42 | Standard Deviation 24.9 | Pain Scores on the Visual Analog Scale |
| Pain Scores on the Visual Analog Scale | Experimental Group - Participants Receiving Trigger Point Injections | Change from week 2 to week 6 follow-up | 30 | Standard Deviation 32.79 | Pain Scores on the Visual Analog Scale |
| Pain Scores on the Visual Analog Scale | Sham Comparator - Participants Not Receiving Trigger Point Injections | Change from week 2 to week 6 follow-up | 28.33 | Standard Deviation 18.93 | Pain Scores on the Visual Analog Scale |
| Opioid Use | Experimental Group - Participants Receiving Trigger Point Injections | POD1 | 50.08 | Standard Deviation 36.89 | MME |
| Opioid Use | Sham Comparator - Participants Not Receiving Trigger Point Injections | POD1 | 68.60 | Standard Deviation 33.8 | MME |
| Opioid Use | Experimental Group - Participants Receiving Trigger Point Injections | week 2 | 23.09 | Standard Deviation 12.21 | MME |
| Opioid Use | Sham Comparator - Participants Not Receiving Trigger Point Injections | week 2 | 19.09 | Standard Deviation 16.69 | MME |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Experimental Group - Participants Receiving Trigger Point Injections | 6 | |
| Overall Study | STARTED | Sham Comparator - Participants Not Receiving Trigger Point Injections | 5 | |
| Overall Study | Post Operative Day (POD) 1 | Experimental Group - Participants Receiving Trigger Point Injections | 6 | |
| Overall Study | Post Operative Day (POD) 1 | Sham Comparator - Participants Not Receiving Trigger Point Injections | 5 | |
| Overall Study | Week 2 | Experimental Group - Participants Receiving Trigger Point Injections | 6 | |
| Overall Study | Week 2 | Sham Comparator - Participants Not Receiving Trigger Point Injections | 5 | |
| Overall Study | Week 6 | Experimental Group - Participants Receiving Trigger Point Injections | 3 | |
| Overall Study | Week 6 | Sham Comparator - Participants Not Receiving Trigger Point Injections | 3 | |
| Overall Study | COMPLETED | Experimental Group - Participants Receiving Trigger Point Injections | 3 | |
| Overall Study | COMPLETED | Sham Comparator - Participants Not Receiving Trigger Point Injections | 3 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Experimental Group - Participants Receiving Trigger Point Injections | 0 | 6 |
| Total, all-cause mortality | Sham Comparator - Participants Not Receiving Trigger Point Injections | 0 | 5 |
| Total, other adverse events | Experimental Group - Participants Receiving Trigger Point Injections | 0 | 6 |
| Total, other adverse events | Sham Comparator - Participants Not Receiving Trigger Point Injections | 0 | 5 |
| Total, serious adverse events | Experimental Group - Participants Receiving Trigger Point Injections | 0 | 6 |
| Total, serious adverse events | Sham Comparator - Participants Not Receiving Trigger Point Injections | 0 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Experimental Group - Participants Receiving Trigger Point Injections vs Sham Comparator - Participants Not Receiving Trigger Point Injections: deaths from any cause | Trial comparisons |
| Experimental Group - Participants Receiving Trigger Point Injections vs Sham Comparator - Participants Not Receiving Trigger Point Injections: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06955923
GET https://conductscience.org/api/trials/v1/NCT06955923/registered